Skip to content
AgingNexus
☰ Menu

Evidence brief · intervention

Rapamycin / mTOR inhibition

Synthesized from 10 indexed sources · 2026-06-03 MST · preview (no AI key)
Preview synthesis (deterministic, no AI key configured). Set a provider key to generate the full brief.

Synthesis (preview — no live AI key for the active provider):

Across the retrieved literature, senescent-cell burden and chronic inflammation recur as central, interacting drivers, with intervention studies reporting functional gains in model organisms. Key works: [1][2][3][4][5].

Set the active provider's API key to generate full model-written analysis.

Sources

  1. [1] Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy
  2. [2] Upstream and downstream of mTOR
  3. [3] Autophagy mediates the mitotic senescence transition
  4. [4] PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
  5. [5] The Targets of Curcumin
  6. [6] Protein misfolding in neurodegenerative diseases: implications and strategies
  7. [7] Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease
  8. [8] mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review
  9. [9] Integrative Omics Reveal Female-Specific Benefits of p16<sup>+</sup> Cell Clearance in Aging Mice.
  10. [10] SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways.
All Rapamycin / mTOR inhibition works → Intervention dossier →